ClinicaliQ Trial Snapshot
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. — Active Not Recruiting • Phase III • NCT05985915.
- Long-term safety and effectiveness study of ianalumab, a new drug treatment for patients with Sjögren's syndrome.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 [NCT05350072] or CVAY736A2302 [NCT05349214]). Conditions: Sjogrens Syndrome Interventions: Ianalumab (VAY736), Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 612 participants